IOncology

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) commenced in San Francisco on January 23, 2025. During the conference, Dr. Ying Yuan from The Second Affiliated Hospital of Zhejiang University School of Medicine presented the latest survival data and subgroup analysis from the BBCAPX study. Oncology Frontier had the privilege of discussing the updated findings with Dr. Ying Yuan. This article summarizes the key insights from the study to provide valuable updates for clinicians and researchers.

Presented at SABCS 2024 by Dr. Vicente Valero, the NRG-BR004 trial evaluated adding atezolizumab to first-line THP therapy in HER2+ metastatic breast cancer (MBC).Key Findings:PFS: 38.1 months (atezolizumab) vs. 22.2…

At the San Antonio Breast Cancer Symposium (SABCS) 2024, Robert K. Hills from the University of Oxford presented groundbreaking findings on behalf of the Early Breast Cancer Trialists’ Collaborative Group…

On the 25th, the Brazilian Ministry of Health announced the confirmation of two fatal cases caused by Orupuche fever. The deceased were two women from the inland region of Bahia State, both under the age of 30 and without any other illnesses. These are the first recorded fatalities due to Orupuche fever worldwide.

For advanced HR+/HER2- breast cancer patients with progression after CDK4/6i treatment, would you prefer endocrine therapy or ADC (antibody-drug conjugate) treatment? In the "In-depth Debate" session of the 2024 Breast Cancer Summer Forum - Northern Salon, Dr. Xu Liang from Peking University Cancer Hospital and Dr. Nanlin Li from Xijing Hospital of Air Force Medical University expressed their views. Dr. Xu Liang favored endocrine therapy, while Dr. Nanlin Li preferred ADC treatment. After the forum, Oncology Frontier invited both experts to elaborate on their perspectives.

For patients with recurrent metastatic triple-negative breast cancer (TNBC), would you choose "chemotherapy + immunotherapy" or "ADC" for treatment? At the 2024 Breast Cancer Summer Forum·Northern Salon "In-Depth Analysis" session, Dr. Wei Li from Jiangsu Provincial People's Hospital and Dr. Shaohua Zhang from the Chinese PLA General Hospital presented their respective viewpoints. Dr. Wei Li expressed a preference for "chemotherapy + immunotherapy," while Dr. Shaohua Zhang opted for "ADC." Following the session, Oncology Frontier invited the two experts to elaborate on their perspectives.

For neoadjuvant immunotherapy in triple-negative breast cancer (TNBC), do you prefer the "TP-AC" or "TP" regimen? At the 2024 Breast Cancer Summer Forum · Northern Salon's "Raising Questions and Seeking Answers" session, Dr. Qiang Zhang from Liaoning Cancer Hospital and Dr. Li Wang from Xingtai People's Hospital presented their viewpoints. Dr. Qiang Zhang favors the TP-AC regimen, while Dr. Li Wang opts for the TP regimen. After the session, Oncology Frontier invited both experts to elaborate on their perspectives.

At SABCS 2024, Dr. Erica Mayer presented findings from the TBCRC 056 Phase II trial, which investigated the combination of the PARP inhibitor niraparib and anti-PD-1 therapy dostarlimab in neoadjuvant…

Could the gut microbiome be the missing link in understanding eating disorders? A groundbreaking study led by Dr. Sabrina J.P. Huwart, Dr. Nuria Morales-Puerto, and Dr. Amandine Everard (Université catholique de Louvain) sheds light on the interplay between gut microbiota, neuroinflammation, and food reward alterations—a critical factor in the development of eating disorders like anorexia nervosa, bulimia nervosa, and binge eating disorder.

At the San Antonio Breast Cancer Symposium (SABCS) 2024, Joyce O’Shaughnessy presented findings from the KEYNOTE-522 trial, a phase 3 study evaluating pembrolizumab in combination with chemotherapy for early-stage triple-negative…